News
The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...
Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback